|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Celgene_Corporation
gptkb:NantKwest
gptkb:Zymeworks
gptkb:Immunomedics
gptkb:Myokardia
gptkb:Celerion
2019
2020
2021
2022
2023
September 2020
November 2020
January 2020
Myocardia
|
|
gptkbp:advertising
|
gptkb:Jill_A._Dyer
gptkb:Lamberto_Andreotti
gptkb:John_A._McCarthy
gptkb:Michael_J._McCarthy
gptkb:David_Elkins
gptkb:Jill_D._Dyer
gptkb:Michael_A._Gold
gptkb:Michael_R._McGarry
gptkb:Michael_A._R._Henson
David_A._Elkins
|
|
gptkbp:CEO
|
Giovanni Caforio
|
|
gptkbp:clinicalTrials
|
cancer treatments
cardiovascular treatments
immunology treatments
|
|
gptkbp:employees
|
30,000+
|
|
gptkbp:founded
|
1887
|
|
gptkbp:founder
|
gptkb:John_Myers
gptkb:William_McLaren_Bristol
|
|
gptkbp:global_presence
|
over 60 countries
|
|
gptkbp:headquarters
|
gptkb:New_York
gptkb:New_York_City
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bristol-Myers Squibb Company
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:market
|
$150 billion (2021)
|
|
gptkbp:operations
|
gptkb:Robert_J._Bertolini
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:NantKwest
gptkb:Pfizer
AbbVie
|
|
gptkbp:philanthropy
|
gptkb:Bristol-Myers_Squibb_Foundation
|
|
gptkbp:products
|
gptkb:Opdivo
Eliquis
Yervoy
|
|
gptkbp:regulatoryCompliance
|
gptkb:Lori_A._Hock
|
|
gptkbp:research
|
gptkb:Thomas_C._Südhof
|
|
gptkbp:research_focus
|
oncology
neuroscience
fibrosis
cardiovascular diseases
immunology
cardiovascular
|
|
gptkbp:revenue
|
$46.4 billion (2020)
|
|
gptkbp:sells
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:social_responsibility
|
gptkb:Angela_A._Hock
|
|
gptkbp:stockExchange
|
BMY
|
|
gptkbp:subsidiary
|
gptkb:Zymeworks
Celgene
Myocardia
|
|
gptkbp:supplyChain
|
David_A._Heller
|
|
gptkbp:tactics
|
gptkb:Susan_L._Hockfield
|
|
gptkbp:website
|
www.bms.com
|